-
Benzinga's Top Pre-Market NASDAQ Losers
Monday, June 6, 2011 - 8:22am | 141Amedisys Inc (NASDAQ: AMED) dipped 7.41% to $27.98 in the pre-market session. AMED shares have dropped 36.54% over the past 52 weeks, while the S&P 500 index has gained 22.09% in the same period. United Therapeutics Corporation (NASDAQ: UTHR) dropped 6.71% to $58.49 in the pre-market trading....
-
Piper Jaffray Reports on PAREXEL International
Friday, June 3, 2011 - 8:43am | 146Piper Jaffray commented on PAREXEL International (NASDAQ: PRXL) in a report released today. In the report, Piper Jaffray was negative in its assessment of its company. Piper Jaffray writes, "The company's FY12 guidance could disappoint given the expectations from the recently signed strategic deal...
-
Piper Jaffray Raises PT On PAREXEL To $20
Friday, June 3, 2011 - 6:14am | 27Piper Jaffray has raised the price target on PAREXEL International (NASDAQ: PRXL) from $18 to $20 and maintains its Underweight rating.
-
Bruker Corporation Announces CFO Transition
Thursday, June 2, 2011 - 4:12pm | 95Bruker Corporation (NASDAQ: BRKR) announced today that Brian Monahan has stepped down from his position as Bruker's Chief Financial Officer for personal reasons, in order to spend more time with his young family. William Knight, Bruker's current Chief Operating Officer and previous CFO, has...
-
Options Brief: Affymetrix, Inc.
Thursday, June 2, 2011 - 10:15am | 72Shares of Affymetrix, Inc. (NASDAQ: AFFX) are higher on the session by 12.10%, trading at $7.04. Overall call volume is now running at 5.28x the daily average, with 23% of all calls traded being purchases on the offer. 3,012 contracts have traded on the session so far. Affymetrix, Inc. develops...
-
NASDAQ Stocks Hitting 52-Week Highs
Thursday, June 2, 2011 - 10:09am | 151Imperial Sugar Company (NASDAQ: IPSU) shares gained 4.07% to create a new 52-week high of $18.39. IPSU shares have surged 72.22% over the past 52 weeks, while the S&P 500 index has gained 19.68% in the same period. Education Management Corporation (NASDAQ: EDMC) shares jumped 29.31% to create...
-
Jefferies Comments On Parexel Guidance
Thursday, June 2, 2011 - 9:28am | 123According to Jefferies, Parexel Int'l (NASDAQ: PRXL) issued FY2012 consolidated service revenue and adjusted EPS guidance ahead of its annual Investor Day (scheduled for June 2), the midpoints of which both coming in ahead of Jefferies and consensus estimates. Jefferies said that its initial...
-
J.P. Morgan Maintains Overweight Rating On Nektar Therapeutics
Thursday, June 2, 2011 - 8:22am | 142According to J.P. Morgan, Nektar Therapeutics (NASDAQ: NKTR) maintains its Overweight rating. J.P. Morgan said that it recently surveyed 50 oncologists to assess current sentiment for NKTR-102 as a potential therapy for metastatic breast cancer (mBC). “At this relatively early juncture, physicians...
-
Oppenheimer Maintains Perform on Affymetrix
Thursday, June 2, 2011 - 8:15am | 125Oppenheimer is out with its report on Affymetrix (NASDAQ: AFFX), maintaining Perform. In a note to clients, Oppenheimer writes, "Today, AFFX announced the appointment of Dr. Frank Witney as president and CEO effective July 1, 2011. Dr. Witney will replace Kevin M. King, who successfully improved...
-
Benzinga's Top Upgrades
Thursday, June 2, 2011 - 8:09am | 135Robert W. Baird upgraded Affymetrix Inc (NASDAQ: AFFX) from “neutral” to “outperform.” AFFX's shares closed at $6.28 yesterday. Affymetrix's trailing-twelve-month revenue is $304.28 million. Analysts at Needham upgraded FSI International Inc (NASDAQ: FSII) from “hold” to “buy.” FSII's shares...
-
PAREXEL Intl Backs FY11 EPS $0.84-$0.88
Wednesday, June 1, 2011 - 4:10pm | 294Today, in conjunction with its Investor Day being held tomorrow in New York City, PAREXEL International Corporation (Nasdaq: PRXL) announced forward-looking earnings expectations for the fourth quarter of Fiscal Year 2011 (ending June 30, 2011), for Fiscal Year 2011, and for Fiscal Year 2012....
-
Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer
Wednesday, June 1, 2011 - 12:13pm | 225Hapoalim Securities is terminating coverage of Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), Pfizer (NYSE: PFE), Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS), Amarin (NASDAQ: AMRN), Amylin (NASDAQ: AMLN), Arena Pharmaceuticals (NASDAQ: ARNA), Auxilium (NASDAQ: AUXL),...
-
Hapoalim Cutting Ocverage On Multitude Of Names
Wednesday, June 1, 2011 - 11:48am | 237Hapoalim Securities announced it would be terminating coverage of a slew of pharmaceutical names due to an analyst departure. The names affected are Bristol-Myers (NYSE: BMY), Eli Lilly (NYSE: LLY) Merck (NYSE: MRK) Pfizer (NYSE: PFE) Acorda (NASDAQ: ACOR), Alkermes (NASDAQ: ALKS) Amarin (NASDAQ:...
-
Alimera Sciences Confirms ILUVIEN NDA Resubmission Has Been Accepted by the FDA
Wednesday, June 1, 2011 - 11:41am | 138Less than one hour before the close yesterday, Benzinga heard positive rumors that the NDA for ILUVIEN, which was resubmitted roughly two weeks ago, had been accepted by the Food and Drug Administration. The drug, which is a joint venture between pSivida (NASDAQ: PSDV) and Alimera Sciences (...
-
Affymetrix Appoints Frank Witney as President, CEO
Wednesday, June 1, 2011 - 9:55am | 51Affymetrix, Inc. (Nasdaq: AFFX) today announced that Dr. Frank Witney has been appointed president and chief executive officer, effective July 1, 2011. Dr. Witney will succeed Kevin M. King who has resigned as Affymetrix's president and chief executive officer, effective June 30, 2011, to pursue...